If your microbiome report flags low diversity, reduced richness, or a Shannon index below a vendor “optimal” band, you are looking at a summary statistic, not a diagnosis. Alpha diversity counts how varied the microbial community is within that one stool sample. It says nothing by itself about which species matter, whether you have small-intestinal overgrowth, or what you should eat.
This page explains what the number means in research, why consumer thresholds are difficult to validate, and when a low score is and is not useful context.
Alpha diversity vs beta diversity (quick distinction)
| Term | Question it answers | On a typical report |
|---|---|---|
| Alpha diversity | How diverse is this sample? | Shannon index, Simpson, observed species/ASVs, “richness” |
| Beta diversity | How different is this sample from others? | Often not shown; underlies clustering, enterotype labels, PC plots |
Reports usually surface alpha because it is easy to reduce to one number. Composition (which taxa are present) often carries more actionable information than the diversity score alone.
What diversity measures mean
Microbiome studies quantify alpha diversity in several related ways:
| Measure | What it reflects | Typical report label |
|---|---|---|
| Richness | Number of distinct taxa detected (OTUs, ASVs, or species) | “Observed species,” Chao1, “species count” |
| Evenness | How evenly abundance is spread across taxa | Implicit in Shannon/Simpson |
| Shannon index | Richness + evenness (sensitive to rare taxa) | “Shannon diversity,” “H′“ |
| Simpson index | Dominance-sensitive diversity metric | Less common on consumer panels |
Functional redundancy matters ecologically: many different taxa can perform overlapping metabolic roles, so more species does not always mean more distinct functions, and fewer detected species does not always mean worse function (Lozupone et al., 2012).
All of these metrics depend on what was sequenced (16S vs shotgun), sequencing depth (deeper sequencing finds more rare taxa → higher apparent richness), and bioinformatics choices (clustering thresholds, database). A “low” Shannon score on a shallow 16S run is not directly comparable to shotgun metagenomics from another lab.
How consumer reports calculate and display diversity
Labs rarely publish full pipelines, but common patterns include:
- Cluster sequences into OTUs/ASVs or assign species from metagenomic reads.
- Rarefy or normalize counts (methods vary; affects richness).
- Compute Shannon, Simpson, or observed taxa for that sample.
- Compare to a reference cohort of other customers or public datasets and flag “low” vs “optimal.”
Important limits:
- Detection ≠ presence. Absence from a list may mean below detection limit, not absent from the gut.
- Stool samples the colon, not the small intestine, diversity there does not map cleanly to upper-GI symptoms (SIBO hub).
- Cross-lab comparison is unreliable. Meta-analyses show that extraction kit, 16S variable region, and platform can shift diversity estimates enough to obscure biology (Lozupone et al., 2013 meta-analysis).
There is no internationally agreed clinical reference range for stool alpha diversity in healthy adults, analogous to blood test intervals. Vendor “optimal” bands are internal reference cohorts, not validated diagnostic cut-offs.
Reference ranges and “low diversity” flags
When a report says your diversity is low, ask:
| Question | Why it matters |
|---|---|
| Low compared to what? | Vendor mean, public HMP/MetaHIT data, or age-matched subgroup? |
| Which index? | Shannon, observed species, and proprietary “health scores” differ. |
| Same method as last time? | Changing labs usually invalidates trend lines (Retesting). |
| Recent antibiotics, travel, or illness? | Acute drops are expected and often partially recover (Palleja et al., 2018). |
The Human Microbiome Project showed that stool communities are among the most species-rich body sites studied, but healthy people still span a wide range of alpha diversity values, and within-person variation is usually smaller than between-person variation at a given time point (HMP Consortium, 2012).
Higher diversity is not a wellness score. Asymptomatic populations include both high- and lower-diversity profiles depending on diet, geography, and genetics (Rinninella et al., 2019). Treating “maximize diversity” as a goal can push unnecessary supplement stacks without symptom benefit.
When low diversity is expected vs when it may matter
Often expected (usually not an emergency on its own)
| Context | Research pattern |
|---|---|
| Recent antibiotics | Acute ↓ richness; partial recovery over weeks–months; composition may stay altered (Palleja et al., 2018) |
| Strict long-term low-fiber or low-FODMAP diets | ↓ fermentable substrates; some trials report ↓ Bifidobacterium and related taxa (FODMAPs, Dietary fiber) |
| Single timepoint noise | Day-to-day technical and dietary variation |
| Lower sequencing depth | Fewer rare taxa called → artificially lower richness |
Where reduced alpha diversity is a consistent research finding
| Context | Evidence strength | Caveat |
|---|---|---|
| Active diarrhoeal illness | Strong in meta-analysis | Acute physiology, not chronic “gut type” (Duvallet et al., 2017) |
| Inflammatory bowel disease (IBD) | Meta-analyses show ↓ alpha diversity vs controls, often more in Crohn’s than UC | Stool vs biopsy differs; calprotectin/endoscopy drive care, not diversity score |
| Some post-antibiotic states | Documented; recovery variable | Richness may normalize while composition stays shifted |
Where low diversity is not a reliable signature
| Context | Why |
|---|---|
| IBS (functional gut) | Individual studies conflict; meta-analyses find inconsistent or small effects, IBS cannot be ruled in or out from diversity alone (Duvallet et al., 2017) |
| General “gut health” marketing | No validated threshold separates healthy from symptomatic without symptoms and clinical context |
| Obesity / metabolic health alone | Associations exist in cohorts but effect sizes are debated and not clinically actionable as a single number |
If you have alarm symptoms (weight loss, blood in stool, persistent fever, anaemia), low diversity on a consumer test does not exclude organic disease, see Red flags.
Diversity scores vs “dysbiosis” labels
Reports often pair low diversity with dysbiosis or poor gut health scores. These are related but not identical:
| Label | Typical meaning |
|---|---|
| Low alpha diversity | One mathematical summary of your sample |
| Dysbiosis flag | Often combines diversity + distance from vendor reference + opportunistic taxa rules |
You can have composition shifts (specific taxa up or down) with modest diversity change, or low diversity after antibiotics without meeting a vendor’s full “dysbiosis” pattern. See Dysbiosis for how that term is used, and misused, on panels.
Do not conclude that low diversity automatically requires probiotics, antimicrobials, or restrictive diets. Interventions should follow symptoms, clinical workup, and evidence for that endpoint, not a single index.
Retesting and trends
Alpha diversity is most informative longitudinally when:
- Same company, same assay, same sample type (stool)
- Stable diet and medication context is noted
- Enough time has passed after antibiotics or major diet change (often weeks to months)
A rise in Shannon index after a probiotic course may reflect transient passage of the administered strain or deeper sequencing, not necessarily lasting ecosystem change (Probiotics & prebiotics, Retesting over time).
Franzosa and colleagues showed that individual gut profiles can be recognizable over time even when diversity metrics fluctuate, identity is carried by specific strains and gene markers as much as by global diversity (Franzosa et al., 2019, personalized signatures).
What not to conclude from your diversity score
| If the report says… | Do not conclude… |
|---|---|
| Low diversity | You are permanently unhealthy or need a “microbiome reset” |
| High diversity | You are protected from IBS, IBD, or infection |
| Below “optimal range” | The vendor threshold is a validated medical reference interval |
| Low diversity + IBS symptoms | IBS is proven microbiome-caused (IBS workup is clinical) |
| Single low result | You must take probiotics (strain-specific evidence varies) |
Related pages
- Reading your microbiome report, hub for report lines
- Dysbiosis, ecological “imbalance” labels
- Post-antibiotic recovery, expected diversity drops
- Retesting over time, valid comparisons
- Gut inflammation markers, when calprotectin matters more than diversity